News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus

Total Page:16

File Type:pdf, Size:1020Kb

News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities. For now, the after identifying clusters of cases among fam- been confirmed in other countries, in Asia, the World Health Organization (WHO) has held ilies, as well as transmission from patients to United States and Europe. off declaring a public-health emergency of health-care workers. Monitoring the rate at Nature | Vol 577 | 30 January 2020 | 605 ©2020 Spri nger Nature Li mited. All ri ghts reserved. News in focus which new cases appear, and when symptoms without symptoms can infect others. A study3 and detecting the virus, the dramatic jump is began for each case, should reveal how easily of a cluster of six infections in a family in concerning. “It’s very much a dynamic picture, the virus passes between humans and whether Shenzhen identified a child who was infected and until we have an indication that cases the outbreak has the potential to persist. with the virus but showed no symptoms. If are declining, it’s going to continue to be of One figure that epidemiologists want is the such asymptomatic cases are common and concern,” she says. number of people that someone with the virus these individuals can spread the virus, then But MacIntyre also notes that researchers tends to infect — known as R0. An R0 of more than containing its spread will be much more dif- are struggling to accurately model the out- 1 means that countermeasures, such as quaran- ficult, researchers say. Key to controlling the break, and to predict how it might unfold, tine, will be needed to contain the spread. The SARS virus was the fact that few cases were because the case-report data being released WHO last week published an estimated R0 of asymptomatic. by Chinese authorities are incomplete. “What 1.4–2.5. Other teams suggest slightly higher “Defining the scale of asymptomatic trans- we need to identify is when people got sick, not 1,2 values . These estimates are similar to the R0 mission remains key: if this is a rare event then when the cases were reported, and all we’ve of SARS during the early stages of the 2002–03 its impact should be minimal in terms of the seen so far is when the cases were reported.” outbreak, and of the novel strain of H1N1 influ- overall outbreak,” Jonathan Ball, a virologist enza that caused a pandemic in 2009. But they at the University of Nottingham, UK, said in a How deadly is the virus? are higher than R0 values estimated during out- statement distributed by the UK Science Media High rates of pneumonia among the first breaks of the Middle East respiratory syndrome people infected had many researchers wor- (MERS) virus, a coronavirus similar to SARS. “Defining the scale of ried that the Wuhan virus was especially “Now it’s in the range of these other impor- pernicious. Those concerns have receded tant epidemics, and that indicates the potential asymptomatic transmission slightly, as more mild cases have turned up. that it will cause a similar scale of public-health remains key.” With some 100 deaths in more than 4,500 concern if nothing else happens,” says reported cases, the virus does not seem to be Mark Woolhouse, an epidemiol ogist at the as deadly as SARS — which killed around 10% University of Edinburgh, UK. Centre. “But, if this transmission mode is con- of the people it infected. But “It’s too early But researchers caution that R0 estimates tributing significantly then control becomes to be sanguine about the severity”, says Neil come with large uncertainties because of gaps increasingly difficult.” Ferguson, a mathematical epidemiologist at in the data, and the assumptions used to cal- One way to determine whether symp- Imperial College London. culate the figure. They also point out that the tom-free people can spread the virus would R0 is a moving target and that estimates of the be to study its spread in individual households Where did the virus come from? figure change over the course of an outbreak — in China, says Sheila Bird, a biostatistician at Authorities are working on the theory that the as control measures are implemented. In the the University of Cambridge, UK. By monitor- virus originated in an unidentified animal or coming days, health authorities and research- ing all the members of a household in which animals, and spread to humans at an animal and ers will be looking for signs that the travel one person is infected, it should be possible to seafood market in Wuhan, which is now closed. restrictions in Wuhan and other Chinese cities, determine who else contracts the virus and how. Identification of the animal source of the virus and other steps taken by to stem transmission, Such studies would also be helpful for identi- could help officials to control the current out- have reduced the R0 there. fying ways of stopping spread in households, break and gauge its threat — and potentially Bird adds. prevent future epidemics, say researchers. Can infected people spread the Raina MacIntyre, an epidemiologist at the Genetic sequencing suggests that the virus without showing symptoms? University of New South Wales in Sydney, Wuhan virus is related to coronaviruses that Another major unanswered question is Australia, says that although the rise in cases circulate in bats, including SARS and its close whether — and how extensively — people probably reflects an increase in testing for relatives. But other mammals can transmit these viruses — SARS was probably spread to humans by civet cats. The market in Wuhan also sells wild animals. And in a controversial study4 published last week, a team of researchers in China who had performed a genetic analysis suggested that the virus jumped to humans from snakes. But other scientists were sceptical of the study, and said that there is no proof that viruses such as those behind the outbreak can infect spe- cies other than mammals and birds. “Nothing supports snakes being involved,” says David Robertson, a virologist at the University of Glasgow, UK. Many researchers think that the animal host or hosts of the virus won’t be identified without further field and laboratory work. And many hope that genetic tests of animals or environmental sources will turn up clues. A mammal is the most likely candidate, says Cui Jie, a virologist at the Pasteur Institute of Shanghai who was part of a team that identi- PRESS/ZUMA WIRE POTI/PACIFIC VICHAN Public-health staff check the temperatures of people arriving from China at Bangkok airport. fied SARS-related viruses in bats from a cave in Yunnan province in southwestern China 606 | Nature | Vol 577 | 30 January 2020 ©2020 Spri nger Nature Li mited. All ri ghts reserved. ©2020 Spri nger Nature Li mited. All ri ghts reserved. Q&A Rolf Hilgenfeld Structural biologist Rolf Hilgenfeld has been trying to develop a cure for coronaviruses since the 2002–03 outbreak of severe acute respiratory syndrome (SARS). Hilgenfeld, who is based at the University of Lübeck in Germany, is hoping to get into the locked- down city of Wuhan in China to test drug compounds in animals infected with the new coronavirus. He tells Nature about his quest. HECTOR RETAMAL/AFP/GETTY HECTOR Why are you visiting China? The city of Wuhan, China, is on lockdown in an attempt to halt the coronavirus outbreak. After this virus emerged, I contacted collaborators in Wuhan. I have two in 2017. SARS and the new virus are part of a these infections have been licensed. compounds to test against the new virus, subgroup known as betacoronaviruses. Field- A team at China’s National Engineering so I am seeking collaborators who have work in the wake of the SARS outbreak has Research Center for the Emergence Drugs samples of the virus. found such viruses only in mammals, Cui says. in Beijing is working on finding therapies that would work by blocking the receptor on At what stage of development are your What can we learn from the virus’s human cells that the virus latches on to and compounds? genetic sequence? uses to infect the cells.
Recommended publications
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Pandemic.Pdf.Pdf
    1 PANDEMICS: Past, Present, Future Published in 2021 by the Mahatma Gandhi Institute of Education for Peace and Challenges & Opportunities Sustainable Development, 35 Ferozshah Road, New Delhi 110001, India © UNESCO MGIEP This publication is available in Open Access under the Attribution-ShareAlike Coordinating Lead Authors: 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/ ANANTHA KUMAR DURAIAPPAH by-sa/3.0/ igo/). By using the content of this publication, the users accept to be Director, UNESCO MGIEP bound by the terms of use of the UNESCO Open Access Repository (http:// www.unesco.org/openaccess/terms-use-ccbysa-en). KRITI SINGH Research Officer, UNESCO MGIEP The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they Lead Authors: NANDINI CHATTERJEE SINGH are not necessarily those of UNESCO and do not commit the Organization. Senior Programme Officer, UNESCO MGIEP The publication can be cited as: Duraiappah, A. K., Singh, K., Mochizuki, Y. YOKO MOCHIZUKI (Eds.) (2021). Pandemics: Past, Present and Future Challenges and Opportunities. Head of Policy, UNESCO MGIEP New Delhi. UNESCO MGIEP. SHAHID JAMEEL Coordinating Lead Authors: Director, Trivedi School of Biosciences, Ashoka University Anantha Kumar Duraiappah, Director, UNESCO MGIEP Kriti Singh, Research Officer, UNESCO MGIEP Lead Authors: Nandini Chatterjee Singh, Senior Programme Officer, UNESCO MGIEP Contributing Authors: CHARLES PERRINGS Yoko Mochizuki, Head of Policy, UNESCO MGIEP Global Institute of Sustainability, Arizona State University Shahid Jameel, Director, Trivedi School of Biosciences, Ashoka University W.
    [Show full text]
  • COVIPENDIUM Aug4.Pdf
    COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction ...................................................................................................................................................................
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Accelerating Vaccination Against Covid-19
    Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy.
    [Show full text]
  • MRC Centre for Outbreak Analysis and Modelling
    Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats.
    [Show full text]
  • Special Edition - 5Th UPDATE 05/03/21
    IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.
    [Show full text]
  • Vaccines to Prevent Sars-Cov-2 Infection
    CORONAVIRUS DISEASE 2019 (COVID- 19):VACCINES TO PREVENT SARS-COV-2 INFECTION Dr Amitis Ramezani Head of Clinical Research group., Pasteur Institute of Iran Overview of vaccine development • Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the pandemic and are being vigorously pursued. As of winter 2020, several vaccines have become available for use in different parts of the world, over 40 candidate vaccines were in human trials, and over 150 were in preclinical trials. • When most people in a community are vaccinated against a disease, the ability of the pathogen to spread is limited. This is called ‘herd’ or ‘indirect’ or ‘population’ immunity. • When many people have immunity, this also indirectly protects people who cannot be vaccinated, such as very young babies and those who have compromised immune systems. • As with the development of pharmaceuticals, vaccine development progresses through preclinical evaluation and three distinct clinical stages, phases I, II, and III . Traditionally, these steps occur sequentially, and each usually takes several years for completion. SARS-CoV-2 vaccine development has accelerated to an unprecedented pace, with each step occurring over several months. Nevertheless, safety criteria remain stringent. • In the United States, the Food and Drug Administration (FDA) must approve progression to each next step in human trials, from initiation of phase I trials through progression to phase III trials. Steps in vaccine development Actions taken to ensure a
    [Show full text]
  • The History of the International AIDS Society (IAS) Is Intertwined with Its Conferences, and in the Struggle for Evidence and Ex
    The history of the International AIDS Society (IAS) is intertwined with its conferences, and in the struggle for evidence and experience to prevail over ignorance and political expediency in the global response to HIV/AIDS. For an epidemic that was initially identified with stigmatized communities, and which quickly escalated in the poorest and most vulnerable populations on the globe, this was – and continues to be – an enormous challenge. Nevertheless, addressing what HIV scientist and human rights activist, Jonathan Mann referred to as “the epidemic of stigma, discrimination, blame and collective denial” has become as integral to International AIDS Conferences as the search for new and better prevention, care and treatment interventions. The IAS was founded in 1988 to be the agency responsible for planning and implementation of the rapidly-growing International AIDS Conferences at which the most current epidemiological and biomedical knowledge would be presented and debated. At the same time, it became the representative of the international scientific community and often the voice of reason in the controversies that have plagued the response to this epidemic. Before we look at the formal establishment of the IAS, it is important to recall the earliest conferences and the emerging epidemic that drove the need for an evolving global forum on one of the greatest public health challenges we face. The following episode is one of 12 to be released each month in 2013 which will chronologically cover the history of the IAS over the last 25 years. The first International AIDS Conference in Atlanta in 1985 was organized to present an overview of knowledge about this emerging epidemic, including possible aetiology, clinical progression, modes of transmission, epidemiological trends and the new test for Human Immunodeficiency Virus (HIV), recently identified as the causative agent amid much controversy between French and American scientists.
    [Show full text]
  • Pdf Ment and Disease Emergence in Humans and Wildlife
    Peer-Reviewed Journal Tracking and Analyzing Disease Trends pages 853-1040 EDITOR-IN-CHIEF D. Peter Drotman Managing Senior Editor EDITORIAL BOARD Polyxeni Potter, Atlanta, Georgia, USA Dennis Alexander, Addlestone, Surrey, UK Associate Editors Timothy Barrett, Atlanta, Georgia, USA Paul Arguin, Atlanta, Georgia, USA Barry J. Beaty, Ft. Collins, Colorado, USA Charles Ben Beard, Ft. Collins, Colorado, USA Martin J. Blaser, New York, New York, USA Ermias Belay, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA David Bell, Atlanta, Georgia, USA Arturo Casadevall, New York, New York, USA Sharon Bloom, Atlanta, GA, USA Kenneth C. Castro, Atlanta, Georgia, USA Mary Brandt, Atlanta, Georgia, USA Louisa Chapman, Atlanta, Georgia, USA Corrie Brown, Athens, Georgia, USA Thomas Cleary, Houston, Texas, USA Charles H. Calisher, Ft. Collins, Colorado, USA Vincent Deubel, Shanghai, China Michel Drancourt, Marseille, France Ed Eitzen, Washington, DC, USA Paul V. Effler, Perth, Australia Daniel Feikin, Baltimore, Maryland, USA David Freedman, Birmingham, Alabama, USA Anthony Fiore, Atlanta, Georgia, USA Peter Gerner-Smidt, Atlanta, Georgia, USA Kathleen Gensheimer, Cambridge, Massachusetts, USA Stephen Hadler, Atlanta, Georgia, USA Duane J. Gubler, Singapore Nina Marano, Atlanta, Georgia, USA Richard L. Guerrant, Charlottesville, Virginia, USA Martin I. Meltzer, Atlanta, Georgia, USA Scott Halstead, Arlington, Virginia, USA David Morens, Bethesda, Maryland, USA Katrina Hedberg, Portland, Oregon, USA J. Glenn Morris, Gainesville, Florida, USA David L. Heymann, London, UK Patrice Nordmann, Paris, France Charles King, Cleveland, Ohio, USA Tanja Popovic, Atlanta, Georgia, USA Keith Klugman, Seattle, Washington, USA Didier Raoult, Marseille, France Takeshi Kurata, Tokyo, Japan Pierre Rollin, Atlanta, Georgia, USA S.K. Lam, Kuala Lumpur, Malaysia Ronald M.
    [Show full text]
  • For Their Discovery of Human Immunodeficiency Virus
    2008 NOBEL LAUREATES The Nobel Prize in Physiology or Medicine 2008 “for his discovery of “for their discovery human papilloma of human viruses causing immunodeficiency cervical cancer” virus” ) X X I I P P DKFZ SCAN SCAN AKUTIN/ AGUNIA/ S M DEUTSCHES KREBSFORSCHUNGSZENTRUM ( KREBSFORSCHUNGSZENTRUM DEUTSCHES Harald zur Hausen Françoise Luc Montagnier 1/2 of the prize Barré-Sinoussi 1/4 of the prize 1/4 of the prize Born: 1936 Born: 1932 Birthplace: Germany Born: 1947 Birthplace: France Nationality: German citizen Birthplace: France Nationality: French citizen Current position: Nationality: French citizen Current position: Professor Emeritus and Current position: Professor Emeritus and former Chairman and Professor and Director, Director, World Foundation Scientific Director, German Regulation of Retroviral for AIDS Research and Cancer Research Centre, Infections Unit, Virology Prevention, Paris, France Heidelberg, Germany Department, Institut Pasteur, Paris, France PHYSIOLOGY OR MEDICINE 13 Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES Speed read: Finding the culprit identification of the virus associated with AIDS, occurred within just a few months amid a flurry of global research activity directed towards finding the cause of the then-new epidemic. Harald zur Hausen’s suggestion that human papilloma virus (HPV) infection might lie behind cervical cancer flew in the face of general opinion in the early 1970s, which held that another commonly present virus, herpes simplex virus, might be the cause. Realising that there were a multitude of different HPV subtypes, and hypothesising that unknown subtypes might cause the cancer, zur Hausen’s group began a painstaking search for such novel ooking back over the two discoveries rewarded viruses.
    [Show full text]
  • (2005) During the COVID-19 Response
    Biographies of Review Committee members on the Functioning of the International Health Regulations (2005) during the COVID-19 Response AAVITSLAND, Preben Dr Preben Aavitsland is a Senior Consultant in the Domain for infectious disease prevention, health and the environment, Norwegian Institute of Public Health, Oslo, Norway, and a Municipal Medical Officer in Arendal and Froland municipalities, Norway. He has served on two previous IHR Review Committees and one Emergency Committee. Dr Aavitsland is the former state epidemiologist of Norway (2002-2012). He served for 21 years in various posts at the Norwegian Institute of Public Health until 2012, including several leading roles, such as Director of Preparedness. He was the Norwegian member of the Advisory Forum of the European Centre for Disease Prevention and Control (ECDC) and the EU’s Network Committee for Communicable Diseases. AGUILERA, Ximena Director, Center of Epidemiology and Health Policy, Faculty of Medicine, Universidad del Desarrollo, Santiago, Chile. Currently dedicated to teaching and research in applied epidemiology to health policy and communicable diseases Dr Aguilera is also President of the Chilean Society of Public Health and Member of the Chilean Society of Infectious Diseases. Dr Ximena Aguilera, MD is a Specialist in Public Health, Master in Public Health, Residence in International Health at the Pan-American Health Organization and formerly Senior Advisor in Communicable Diseases (2008-10) where among other duties she coordinated the technical response to the H1N1 pandemic. Previously, she was the Chief of Health Planning Division at the Ministry of Health in Chile (2005-08) and Head of the Department of Epidemiology at the same institution (1999-05).
    [Show full text]